Get the Stockscreener App
1.21
2.42%
-0.03
Renovorx Inc stock is traded at $1.21, with a volume of 65,266.
It is down -2.42% in the last 24 hours and down -4.72% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$1.24
Open:
$1.24
24h Volume:
65,266
Relative Volume:
0.42
Market Cap:
$44.25M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-2.1228
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
-4.72%
1M Performance:
-4.72%
6M Performance:
-11.03%
1Y Performance:
-1.63%
1-Day Range:
$1.21
$1.24
1-Week Range:
$1.20
$1.31
52-Week Range:
$0.75
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.21 | 45.35M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Renovorx Inc Stock (RNXT) Latest News
Exit strategy if you’re trapped in RenovoRx Inc.Swing Trade Entry and Exit Point Analysis - Newser
Will RenovoRx Inc. price bounce be sustainableFree Capital Growth With Controlled Risk Picks - Newser
Why RenovoRx Inc. stock attracts strong analyst attentionDaily Market Momentum and Pressure Analysis - Newser
Will RenovoRx Inc. stock recover after recent dropMinimal Risk Growth Investment Opportunity Analysis - Newser
Can you recover from losses in RenovoRx Inc.Short-Term Stock Trend Forecast Guide - Newser
How RenovoRx Inc. stock performs during market volatilityPattern Breakout Tracker with Screener Tools - Newser
What are analysts’ price targets for RenovoRx Inc. in the next 12 monthsSwing Trade Report For Consistent Profits - jammulinksnews.com
When is RenovoRx Inc. stock expected to show significant growthReal Time Strategy For Consistent Profits - jammulinksnews.com
What makes RenovoRx Inc. stock price move sharplyFree Wealth Building Stock Market Ideas - Newser
How volatile is RenovoRx Inc. stock compared to the marketAdvanced Screener Growth Plan For Fast Growth - jammulinksnews.com
Can swing trading help recover from RenovoRx Inc. lossesDaily Equity Signal Strength Summary Report - Newser
RenovoRx Inc. stock prediction for this weekFree Short Term High Yield Stock Tips - Newser
New Product Launches: Will They Boost RenovoRx Inc. Stock in 2025Fast Entry High Potential Stock Alerts Triggered - metal.it
Heatmap analysis for RenovoRx Inc. and competitorsBuy Signal System Based on Price Action - Newser
Moving Average Trends for RenovoRx Inc. Stock: What They IndicateShort-Term Stock Trend Forecast Guide - Newser
Ellis Martin Report: Redefining Cancer TreatmentRenovoRx, Inc. (NASDAQ:RNXT) CEO Shaun Bagai on Targeted Pancreatic Therapy - ABN Newswire
RenovoRx launches multi-centre post-marketing registry study - European Pharmaceutical Manufacturer
RenovoRx Inc. Moves Into Bullish Territory Based on MACDLow Risk High Return Opportunities Identified - metal.it
Is this a good reentry point in RenovoRx Inc.Oversold Stock Bounce Playbook Generator - Newser
What are RenovoRx Inc. company’s key revenue driversDaily Trading Opportunities For Fast Growth - jammulinksnews.com
Should I hold or sell RenovoRx Inc. stock in 2025Consistently high returns - jammulinksnews.com
Pancreatic Ductal Adenocarcinoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix - Barchart.com
RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors - BioSpace
RenovoRx launches post-marketing study to advance real-world use of RenovoCath Device - Medical Economics
RenovoRx to launch post-marketing registry study for cancer device By Investing.com - Investing.com Nigeria
RenovoRx to launch post-marketing registry study for cancer device - Investing.com Australia
What markets is RenovoRx Inc. expanding into Is FORR stock a good long term investment optionDiscover stocks with explosive growth potential - jammulinksnews.com
How does RenovoRx Inc. compare to its industry peersAchieve breakthrough investment performance - jammulinksnews.com
What institutional investors are buying RenovoRx Inc. stockAchieve rapid wealth accumulation with smart picks - jammulinksnews.com
Is RenovoRx Inc. a growth stock or a value stockHigh-octane gains - jammulinksnews.com
How many analysts rate RenovoRx Inc. as a “Buy”Capitalize on high-yield stock opportunities - jammulinksnews.com
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):